Background-The clinical efficacy of alcohol septal ablation for obstructive hypertrophic cardiomyopathy (HCM) has been demonstrated, but the long-term effects of the procedure remain uncertain. This study examined the survival of patients after septal ablation performed in a tertiary HCM referral center. Methods and Results-We examined 177 patients (mean age, 64 years; 68% women) who underwent septal ablation at our institution. Over a follow-up of 5.7 years, survival free of all mortality was no different than the expected survival for a comparable general population, and similar to that of age-and sex-matched patients who underwent isolated surgical myectomy (8-year survival estimate, 79% versus 79%; Pϭ0.64). For the end point of documented sudden cardiac death or unknown cause of death, the incidence per 100 person-year follow-up was 1.31 (95% confidence interval, 0.60-2.38). Residual left ventricular outflow tract gradient after ablation was an independent predictor of long-term survival free of any death. Conclusions-In this nonrandomized study of carefully selected patients undergoing septal ablation by experienced operators in a tertiary referral HCM center, long-term survival was favorable and similar to that of an age-and sex-matched general population, and to patients undergoing surgical myectomy, as well, without an increased risk of sudden cardiac death. (Circulation. 2012;126:2374-2380.)
D ynamic left ventricular outflow tract (LVOT) obstruction is an important component of the pathophysiology of hypertrophic cardiomyopathy (HCM) and can lead to debilitating symptoms of dyspnea, angina, and syncope in a subset of these patients. [1] [2] [3] For those with drug-refractory symptoms, the standard of care is surgical myectomy, which is associated with a low procedural mortality and lasting clinical efficacy when performed in experienced centers. 4, 5 As an alternative therapeutic option, percutaneous alcohol septal ablation has been adopted in an increasing number of cardiac centers worldwide. 6 -8 Early clinical efficacy with septal ablation has been demonstrated in short-term studies, but there continues to be uncertainty with regard to the durable effects of the procedure and its impact on late survival and ventricular arrhythmias in patients with HCM. [7] [8] [9] [10] [11] 
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Accordingly, the present study was undertaken to examine the long-term outcome of septal ablation in patients with obstructive HCM.
Methods

Study Patients
This study was approved by the Mayo Clinic Institutional Review Board. All patients were evaluated at the Mayo Cardiomyopathy Clinic. The diagnosis of HCM was based on typical clinical, electrocardiographic, and echocardiographic features, with ventricular myocardial hypertrophy occurring in the absence of any other accountable cardiac or systemic disease. 12, 13 As previously described, each patient met the following criteria to be considered for septal ablation: (1) severe, drug-refractory cardiovascular symptoms, which was defined New York Heart Association class III/IV dyspnea, Canadian Cardiac Society angina class III/IV, or disabling syncope; (2) dynamic LVOT obstruction due to systolic anterior motion of the mitral valve, with an LVOT gradient Ն30 mm Hg at rest or Ն50 mm Hg with provocation (eg, Valsalva strain, amyl nitrate inhalation, and postectopic beat analysis); (3) ventricular septal thickness Ն15 mm; (4) no significant intrinsic mitral valve disease; (5) absence of need for concomitant cardiac surgical procedure (eg, bypass grafting and valve replacement); (5) suitable coronary anatomy; and (6) and informed patient consent. 14 Significant dynamic LVOT obstruction was documented by 2-dimensional and Doppler echocardiography or, in those cases where echocardiography was insufficient, by invasive hemodynamic catheterization with provocation. 15 Coronary anatomy was deemed suitable for septal ablation when the size (usually Ն1.5 mm) and course of the target artery could be approached with conventional equipment for percutaneous coronary intervention. The same criteria of severe, drug-refractory symptoms due to obstructive HCM were used to determine eligibility for surgical myectomy. The choice of alcohol septal ablation or surgical myectomy was made through a shared decision-making process after discussion of the risks of benefits of each alternative. Between December 4, 1998 and August 31, 2010, 179 patients underwent septal ablation at the Mayo Clinic (Roches-ter, MN). Two of these patients did not provide informed consent for use of their medical record for research purposes in accordance with Minnesota state law, resulting in 177 patients to make up the present cohort. This cohort includes 138 patients previously reported in our short-term follow-up study. 14 
Alcohol Septal Ablation
Invasive hemodynamic evaluation for evaluation of the LVOT gradient at rest and with provocation was performed with transseptal puncture (73%) or retrograde assessment (27%), with rapid acquisition of digital records (5-ms intervals) as previously described. 14, 15 Septal ablation was performed by using previously described catheter techniques. 16 In brief, a slightly oversized, over-the-wire angioplasty balloon was placed in a proximal septal perforator artery from a 6 or 7F left coronary guide catheter with the use of standard percutaneous methods. After balloon inflation, angiographic and echocardiographic contrast was injected through the balloon catheter to identify the perfusion bed of the septal perforator artery. After delineation of the targeted myocardium, 1 to 3 mL of desiccated ethanol was infused slowly over a period of 3 to 5 minutes followed by normal saline flush (1 mL over 2 minutes). The decision to treat additional septal arteries was based on the presence of significant, residual LVOT gradients at rest or with provocation (Ͻ50% reduction with ablation), technically accessible candidate septal arteries, and contrast opacification of myocardium believed to be the substrate contributing to the residual LVOT gradients. This hemodynamic approach with contrast injection also was used for selection of the initial and subsequent septal arteries for ablation in patients who presented to the catheterization laboratory with either a history of latent LVOT obstruction or no resting gradient. In these latter patients, provocable LVOT gradients were assessed to determine need for additional septal ablation. As a precaution in the event of the development of a high-grade atrioventricular block, patients without permanent pacemakers underwent placement of a temporary device during the procedure. All patients were monitored in an intensive care unit setting for at least 3 days after septal ablation.
Clinical Follow-Up
Each patient was contacted to determine vital status, cardiovascular symptoms, potential complications related to septal ablation (eg, ventricular arrhythmias, pacemaker dependency, device malfunction, or infection), and need for additional procedures including further septal reduction therapy (ie, surgical myectomy, repeat septal ablation), pacemaker or defibrillator implantation, and other cardiac surgery. This follow-up evaluation was conducted by the use of mailed questionnaires, telephone contact, and interrogation of the Social Security Death Index. For deceased patients, procurement of death certificates and interviews with next of kin was performed to determine cause of death. Sudden cardiac death was defined as instantaneous and unexpected death with or without documented ventricular fibrillation within 1 hour after a witnessed collapse, in patients who previously were in stable clinical condition, or nocturnal death with no antecedent history of worsening symptoms, in the absence of other etiologies for sudden death (eg, pulmonary embolism). 17 Appropriate discharge of an implanted internal cardioverterdefibrillator (ICD) device for therapy of a lethal arrhythmia (ie, sustained ventricular tachycardia or fibrillation) was considered to be sudden cardiac death in stated analyses. Occurrence of stroke was defined according to standard criteria. 18 
Data Analysis
The primary end points of interest were (a) all-cause mortality and (b) all-cause mortality or need for additional septal reduction therapy combined. Patients with an unknown cause of death were included in the end point of all-cause mortality. The Kaplan-Meier method was used to estimate survival of these end points with 95% confidence intervals (CIs). Expected survival was calculated by using age-and sex-specific mortality rates obtained from the US general population with the use of Census Bureau life tables (http://www.cdc.gov/nchs/ products/life_tables.htm) with SAS Version 9 (SAS Institute, NC). 4, 19, 20 Mortality rates were calculated for each individual in the study and combined to form an expected summary curve for the population. Observed mortality was compared with expected survival by using a 1-sample log-rank test. To compare the outcomes of the septal ablation with surgical myectomy from our institution, data on patients from a previously described cohort who underwent isolated myectomy were analyzed. 4 These patients had undergone isolated myectomy between 1983 and 2001. Isolated myectomy was defined as a procedure in which surgical myectomy was performed as the sole surgical intervention, in the absence of other concomitant cardiac surgery (eg, coronary artery bypass grafting, valve repair or replacement, or aortic aneurysm repair). 4 Patients from this surgical cohort were matched by age and sex in 1:1 fashion to patients who underwent septal ablation in the present study. Survival comparisons between groups were made by using a Cox model stratified by matched pairs. Occurrence of end points per 100 person-year follow-up was calculated with assumption of a normal distribution for the CIs to estimate annual incidence of events. To account for the possibility that patients with unknown cause of death may have had sudden cardiac death, maximal estimates of occurrence were generated in separate analyses by assuming that all patients with unknown causes died of sudden cardiac death. Separate analyses also were performed to include appropriate discharge of an implanted ICD device for therapy of a lethal arrhythmia (ie, sustained ventricular tachycardia or fibrillation) as a sudden cardiac death event.
Cox proportional hazards regression was used to identify variables associated with the study end points that were incorporated into the final multivariate model. Clinical variables known or suspected to impact patient prognosis were chosen, and included age, male sex, hypertension, atrial fibrillation, previous stroke, coronary artery disease, family history of sudden death due to HCM, left ventricular size (end-diastolic and end-systolic diameters), maximal left ventricular wall thickness, left atrial volume, baseline resting LVOT gradient, postprocedural LVOT gradient, injected alcohol volume, and medication use (ie, ␤-antagonist, calcium-channel blocker, angiotensin-converting enzyme inhibitor, and amiodarone). In addition to age and male sex, variables with the most statistically significant associations in the univariate analyses were hierarchically added to the multivariate models. The final number of variables was restricted according to the number of end-point events to avoid overfitting the multivariate model.
Procedural success with alcohol septal ablation was defined as Ն80% reduction in the peak resting and provocable LVOT gradient with a final residual resting gradient of Յ10 mm Hg in the absence of death or need for emergency surgery during hospitalization. These same hemodynamic and clinical criteria also were required to define procedural success in patients with either history of latent LVOT obstruction or no resting gradient in the catheterization laboratory. Comparisons of continuous variables were made with the appropriate test: a t test in cases where the variable distributions were symmetrical and a Wilcoxon rank sum test otherwise. A 1-sample test was used for paired comparisons, and a 2-sample test was used for unpaired comparisons. For comparisons of contingency variables, Fisher exact test was used. All continuous variables are reported as median with interquartile range in parentheses unless otherwise stated.
All authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Patient Population
All 177 patients who underwent septal ablation (age, 65 years; range, 26 -89 years; 68% women) had severe cardiovascular symptoms (New York Heart Association class III/IV dyspnea, 100%; Canadian Cardiac Society class III/IV angina, 39%) ( Table 1) . Patients who underwent surgical myectomy had a lower incidence New York Heart Association class III/IV dyspnea and a greater prevalence of Cana-dian Cardiac Society class III/IV angina; all patients undergoing myectomy had severe, drug-refractory symptoms. The majority of patients (81%) had significant LVOT obstruction at rest on echocardiography (gradient Ն30 mm Hg), with latent obstruction present in the remaining 34 patients (19%). Two patients (1.1%) presented for therapy in the setting of cardiogenic shock. Surgical therapy at an outside institution had previously failed in 3 other patients (1.7%) owing to an incomplete septal myectomy. Among 8 patients who had previously undergone ICD implantation (4.5%), the indications were primary prevention of sudden cardiac death in each case.
Acute and 30-Day Procedural Outcome
Among the patients who underwent septal ablation, procedural success occurred in 132 patients (74.6%) with a median residual LVOT gradient of 5 (15) mm Hg at rest. Two in-hospital deaths occurred after septal ablation (1.1%). 14 Both of these deaths occurred in the 2 patients who had presented with cardiogenic shock. There was no other procedural or in-hospital mortality. Two patients had sustained ventricular tachycardia while hospitalized that led to implantation of an ICD. In addition, 8 other patients underwent ICD implantation during hospitalization for primary prevention of sudden cardiac death. Two patients required urgent surgery for cardiac tamponade (one because of temporary pacemaker placement and one because of transseptal puncture); concomitant surgical myectomy was performed in one of these patients. Of the 36 patients who underwent pacemaker implantation, 24 had device therapy for persistent high-grade atrioventricular block; other pacemaker indications were symptomatic bradycardia, transient atrioventricular block, or left bundle-branch block.
Among the patients undergoing myectomy, 1 patient underwent surgery for cardiogenic shock due to obstructive HCM and died in-hospital. One other patient underwent reoperation for mitral valve repair, and another patient underwent open exploration for postoperative bleeding. Five patients underwent ICD implantation during hospitalization for primary prevention of sudden cardiac death. Table 2 lists other clinical events that occurred within 30 days after each procedure.
Survival
Clinical follow-up was completed in 173 patients (98%) with a median duration of 5.7 (4.9) years (maximum, 11.9 years). Of the four patients lost to follow-up, each was known to be alive, but could not be reached for assessment of symptoms and clinical events.
There were 26 total deaths among the ablation patients at the conclusion of the study period, including the 2 aforementioned in-hospital deaths (14.7% of total population; Table 3 ). Survival free of all-cause mortality among all septal ablation patients at 8 years was 79.4% (95% CI, 71.6%-87.3%; Figure 1 ). This observed survival was comparable to the expected survival for a comparable general US population (79%), and similar to the age-and sex-matched cohort of surgical myectomy patients (79.0%, 71.4%-86.7%, Pϭ0.64 versus ablation; Figure 2 ). Table 3 lists causes of death. The incidence per 100 person-year follow-up of all-cause mortality was 2.51 (95% CI, 1.53-4.00).
Among the patients undergoing septal ablation, 1 additional patient experienced ICD discharge for treatment of monomorphic ventricular tachycardia 66 days after septal ablation. One other patient had inappropriate discharge of an ICD for treatment of supraventricular tachycardia. No other ICD discharges occurred during the study period. For the combined end point of sudden cardiac death and unknown cause of death, the incidence per 100 person-year follow-up was 1.31 (0.60 -2.38). With inclusion of appropriate ICD discharge, this incidence was 1.41 (0.67-2.52).
Among patients who had myectomy, the incidence per 100 person-year follow-up of all-cause mortality was 2.43 (95% CI, 1.48 -3.87). There were no ICD discharge events. For the combined end point of sudden cardiac death and unknown cause of death, the incidence per 100 person-year follow-up was 1.07 (0.44 -2.02).
Clinical Efficacy
Among the 147 surviving ablation patients with clinical follow-up, 99 patients were asymptomatic (Table 3 ). Persistent or recurrent severe symptoms occurred in 20 patients, leading to the need for additional septal reduction therapy in 15 patients. Two of the patients who underwent surgical myectomy after septal ablation died in follow-up, including 1 sudden cardiac death. Among the ablation patients, the 8-year survival free of the combined end point of death and need for additional septal reduction therapy (ie, myectomy or repeat septal ablation) was 69.8% (60.9%-78.8%; Figure 3 ). This survival was lowered than that observed in the patients who had myectomy (78.9%; 71.2%-86.6%; Pϭ0.04), owing to the greater frequency of myectomy in follow-up for patients who had septal ablation (Figure 3) . Nonetheless, the proportion of patients who were alive and free of severe symptoms was similar for those who had septal ablation (78%) and for those who had myectomy (73%; Pϭ0.26).
Predictors of Outcome
Residual LVOT gradient after septal ablation was a significant predictor of long-term survival (Figure 4) . The relation between residual LVOT gradient after septal ablation and long-term outcomes remained significant after multivariate analysis (Tables 4 and 5) .
Discussion
The present investigation is a nonrandomized, retrospective evaluation of alcohol septal ablation performed in a tertiary referral center with expertise in the comprehensive care of patients with HCM. The principal findings of the study are: (1) long-term survival after septal ablation is similar to the expected survival for a similar general US population, and comparable to age-and sex-matched patients who underwent isolated surgical myectomy at our institution. (2) Septal ablation in carefully selected patients can result in durable relief of symptoms in the majority of surviving patients at follow-up, without an increased risk of sudden cardiac death. (3) The severity of the residual LVOT gradient after septal ablation is an important determinant of long-term outcome.
Since the first reporting of alcohol septal ablation, the role of this therapy in the management of symptomatic patients with obstructive HCM has been in need of clarity. 6, 20 Undoubtedly, septal ablation can result in acute hemodynamic relief of LVOT obstruction in selected patients. 6 -11 Nonetheless, there have been concerns regarding its arrhythmogenic potential, the heightened risk of procedural complications, and the paucity of data on the long-term outcome after the iatrogenic infarction, which typically encompasses Ϸ10% of the left ventricular mass. 11, 21, 22 The lack of long-term data on septal ablation has been highlighted in several recent analyses, which have noted that the vast majority of studies have Ͻ3.0 years of average follow-up. 7, 8 These concerns are particularly relevant given the established role and high clinical efficacy of surgical myectomy. 4, 5 Surgical myectomy, when performed in experienced centers, has evolved to become a low-risk operation with success rates of Ͼ90% and has been associated in 1 study with survival comparable to expected mortality rates for a general population of individuals. 4, 5, 21 Accordingly, the present investigation examined the longevity of patients treated with septal ablation at an institution where both percutaneous and surgical options for HCM are routinely practiced. In this study, which evaluates a sizable cohort (nϭ177) over an extended follow-up period, the observed survival free of all-cause mortality (79% at 8 years follow-up) was similar to 2 reference standards for longevity: the expected survival of a comparable US general population and the survival of matched patients with HCM who underwent isolated surgical myectomy. These reference standards were used to account for the relatively older age of the patients who have ablation and to enable comparisons with results achieved with a high level of surgical expertise, in particular, for patients in this age group. Notably, documented ventricular fibrillation or sustained ventricular tachycardia occurred early after the procedure (ie, within 1 month) in 4 patients who had ablation and was observed in 2 other patients in further follow-up. In 12 of the 26 patients undergoing ablation who died, the cause of death could not be determined with certainty. It is highly probable that a number of our patients with unknown cause of death experienced a fatal arrhythmia or heart failure. Similar to previous studies of HCM, noncardiac causes of death were frequent (11 patients or 42% of deaths). 1 To provide estimates on the incidence of sudden cardiac death after ablation, we performed analyses that assumed that patients with unknown cause of death died of fatal arrhythmia and included appropriate ICD discharge, and we subsequently derived a maximal incidence of 1.5% per year (95% CI, 0.8%-2.7%). To help reduce retrospective study bias, the primary end point of interest in the present investigation was survival free of all-cause mortality. 8, 9 Given that the mortality rate of the cohort was similar relative to multiple reference standards, the present study demonstrates that septal ablation in selected patients can be associated with expected survival for a general population.
In patients with HCM, a major goal of septal reduction therapy is the durable relief of dynamic LVOT obstruction and refractory symptoms. The present investigation extends earlier comparative studies of clinical efficacy in patients with septal ablation and surgical myectomy. [23] [24] [25] [26] [27] Survival free of death or need for additional septal reduction therapy at 8-year follow-up was better among patients who underwent myectomy, owing to a greater frequency of subsequent myectomy among patients in whom therapy with septal ablation failed. Nonetheless, overall relief from severe symptoms was comparable at the end of follow-up.
It is important to note that these comparable outcomes were observed in an ablation cohort where acute hemodynamic success (ie, Ն80% gradient reduction and final resting LVOT gradient of Յ10 mm Hg) occurred in the vast majority (75%), resulting in a median residual gradient of 11 mm Hg (meanϭ13 mm Hg). In our institution, septal ablation is performed by only select dedicated invasive operators, leading to a high level of expertise and results that cannot be easily extrapolated to less experienced centers. In addition to the present article, few data on long-term survival in comparison with reference standards are available; further validation of the results is required. 10 Importantly, residual LVOT gradient was an independent predictor of both a greater risk of death and poor symptom relief with septal ablation, as well. Residual LVOT gradients with septal ablation have been reported in several studies to be higher than that observed after surgical myectomy (frequently Ͻ5 mm Hg). 20, [23] [24] [25] [26] [27] A relation between residual LVOT gradient and outcome has been reported previously, although it is not clear if the adverse prognosis is due to attributable hemodynamic perturbation or if residual gradient is a marker of disease complexity. Residual gradients may not be tolerated by younger or highly active individuals. 28, 29 Given that suboptimal outcomes with septal ablation in relatively younger patients have been observed in some studies, consideration has been given to surgical myectomy as the preferred method for septal reduction therapy in this population, especially those Ͻ40 years of age. 4, 21, 28, 30, 31 Nevertheless, it is important to note that this study did not examine potential impact of subacute remodeling and changes in LVOT gradient in follow-up on long-term outcome.
Our findings support the need for a greater understanding of patient selection for septal ablation and further technical advances to improve procedural success. 28 Importantly, septal ablation was only performed after a comprehensive, multidisciplinary evaluation in a setting where surgical myectomy is readily offered to all HCM patients presenting for therapy of drug-refractory symptoms. Procedural mortality for septal ablation was low (1.4%), but other complications are more frequent than with surgery. Fully informed consent with shared decision making by the use of an integrated team approach is an elemental component of the management of these complex patients.
Study Limitations
The retrospective, nonrandomized nature of the present investigation has known limitations, including significant potential for selection bias. Patients undergoing septal ablation more frequently had significant morbidities (eg, coronary artery disease) known to affect the survival of these patients, and these effects may be more evident in a larger patient population or with longer follow-up duration. Multivariate analyses for comparisons between patient groups were performed to help minimize the effects of baseline clinical differences, but these adjustments also have known limitations. Nevertheless, it is noteworthy that survival was similar to expected outcome for a general population of individuals. Notably, the cause of death could not be ascertained in 12 (or 46%) of the 26 deaths that occurred. By assuming all unknown causes of death were due to ventricular arrhythmia, our data allow an estimate of the maximum incidence per year of sudden cardiac death; however, the true incidence of sudden cardiac death could not be determined. Nonetheless, the present cohort exhibited survival free of all causes of death that was similar to accepted reference standards for evaluations of expected versus observed mortality. 4, 19 
Conclusions
Survival after septal ablation with extended follow-up appears favorable and comparable to that of surgical myectomy. Late survival is similar to an age-and sex-matched general US population, without evidence of increased risk of sudden death. These data support the role of septal ablation in the management of patients with drug-refractory symptoms due to obstructive HCM when performed by experienced operators.
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